• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利巴韦林用于接受依鲁替尼治疗的慢性戊型肝炎病毒感染患者

Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients.

作者信息

Protin Caroline, Abravanel Florence, Alric Laurent, Tavitian Suzanne, Obéric Lucie, Izopet Jacques, Martin-Blondel Guillaume, Ysebaert Loic

机构信息

Hematology Department, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.

Laboratory of Virology, CHU Purpan, Toulouse, France.

出版信息

Open Forum Infect Dis. 2019 Jul 28;6(9):ofz345. doi: 10.1093/ofid/ofz345. eCollection 2019 Sep.

DOI:10.1093/ofid/ofz345
PMID:31660412
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6798245/
Abstract

Ibrutinib is an oral first-in-class Bruton's tyrosine kinase inhibitor approved for the therapy of various B-cell lymphoid malignancies. Among ibrutinib-related infections, viral hepatitis are poorly described. We report our single-center experience with 4 cases of chronic hepatitis E virus infection and their management with ribavirin.

摘要

依鲁替尼是一种口服的一流布鲁顿酪氨酸激酶抑制剂,被批准用于治疗各种B细胞淋巴瘤。在与依鲁替尼相关的感染中,病毒性肝炎的描述较少。我们报告了我们单中心对4例戊型肝炎病毒慢性感染病例及其使用利巴韦林治疗的经验。

相似文献

1
Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients.利巴韦林用于接受依鲁替尼治疗的慢性戊型肝炎病毒感染患者
Open Forum Infect Dis. 2019 Jul 28;6(9):ofz345. doi: 10.1093/ofid/ofz345. eCollection 2019 Sep.
2
Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy.在接受伊布替尼治疗的乙型肝炎病毒表面抗原阴性隐匿性乙型肝炎患者中乙型肝炎病毒再激活。
Virol J. 2023 Aug 1;20(1):168. doi: 10.1186/s12985-023-02140-w.
3
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.布鲁顿酪氨酸激酶抑制剂依鲁替尼用于B细胞恶性肿瘤的研发。
Ann N Y Acad Sci. 2015 Nov;1358:82-94. doi: 10.1111/nyas.12878. Epub 2015 Sep 8.
4
Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment.淋巴浆细胞淋巴瘤及依鲁替尼治疗期间的慢性戊型肝炎病毒感染
Pathogens. 2019 Aug 22;8(3):129. doi: 10.3390/pathogens8030129.
5
The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.布鲁顿酪氨酸激酶抑制剂依鲁替尼在治疗淋巴系统恶性肿瘤方面具有显著疗效。
Pharmacotherapy. 2014 Mar;34(3):303-14. doi: 10.1002/phar.1366. Epub 2013 Dec 12.
6
Successful Control of Hepatitis B Virus Reactivation following Restart of Ibrutinib in Chronic Lymphocytic Leukaemia.慢性淋巴细胞白血病患者重新使用伊布替尼后成功控制乙肝病毒再激活
Case Rep Hematol. 2021 Oct 21;2021:1862446. doi: 10.1155/2021/1862446. eCollection 2021.
7
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.伊布替尼,一种布鲁顿酪氨酸激酶抑制剂,一种新型隐球菌病的危险因素。
Med Mal Infect. 2020 Nov;50(8):742-745. doi: 10.1016/j.medmal.2020.07.005. Epub 2020 Aug 7.
8
A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.新型布鲁顿酪氨酸激酶抑制剂依鲁替尼的综述
J Oncol Pharm Pract. 2016 Feb;22(1):92-104. doi: 10.1177/1078155214561281. Epub 2014 Nov 25.
9
Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.布鲁顿酪氨酸激酶抑制剂对急性心肌梗死患者血小板聚集的影响。
Thromb Res. 2019 Jul;179:64-68. doi: 10.1016/j.thromres.2019.04.024. Epub 2019 Apr 24.
10
Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.布鲁顿酪氨酸激酶抑制剂在血液系统恶性肿瘤之外的新适应症
J Clin Med. 2018 Mar 21;7(4):62. doi: 10.3390/jcm7040062.

引用本文的文献

1
Chronic hepatitis E virus-induced spinal cord atrophy in a patient with chronic lymphatic leukemia: a case report and interdisciplinary management proposal.慢性淋巴细胞白血病患者慢性戊型肝炎病毒诱导的脊髓萎缩:病例报告及跨学科管理建议。
Front Immunol. 2024 Jul 26;15:1445944. doi: 10.3389/fimmu.2024.1445944. eCollection 2024.
2
A Case of Hepatitis E Persistence in a Patient With Myelofibrosis Under Ruxolitinib.一例接受鲁索替尼治疗的骨髓纤维化患者戊型肝炎持续感染病例
ACG Case Rep J. 2021 Nov 19;8(11):e00674. doi: 10.14309/crj.0000000000000674. eCollection 2021 Nov.
3
Viral Hepatitis E and Chronicity: A Growing Public Health Concern.戊型病毒性肝炎与慢性化:日益受到关注的公共卫生问题
Front Microbiol. 2020 Sep 29;11:577339. doi: 10.3389/fmicb.2020.577339. eCollection 2020.
4
HSV-1 Encephalitis in an Elderly Man Receiving Ibrutinib for Waldenstrom's Macroglobulinemia.一名接受伊布替尼治疗华氏巨球蛋白血症的老年男性患单纯疱疹病毒1型脑炎
Case Rep Infect Dis. 2020 Mar 23;2020:6516037. doi: 10.1155/2020/6516037. eCollection 2020.
5
Modulation of Adipose-Derived Mesenchymal Stem/Stromal Cell Transcriptome by G-CSF Stimulation.粒细胞集落刺激因子刺激对脂肪来源间充质干/基质细胞转录组的调控
Stem Cells Int. 2020 Feb 15;2020:5045124. doi: 10.1155/2020/5045124. eCollection 2020.

本文引用的文献

1
The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study.血液恶性肿瘤患者的戊型肝炎负担:一项回顾性欧洲队列研究。
J Hepatol. 2019 Sep;71(3):465-472. doi: 10.1016/j.jhep.2019.04.022. Epub 2019 May 18.
2
Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.在接受伊布替尼治疗的慢性淋巴细胞白血病患者中,用利巴韦林成功治疗慢性戊型肝炎。
Bull Cancer. 2019 Jan;106(1):84-85. doi: 10.1016/j.bulcan.2018.11.011. Epub 2018 Dec 19.
3
Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.激酶抑制剂治疗慢性淋巴细胞白血病的免疫变化
Leuk Lymphoma. 2018 Dec;59(12):2792-2800. doi: 10.1080/10428194.2018.1457147. Epub 2018 May 15.
4
Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: Linking mechanisms with infections.慢性淋巴细胞白血病和靶向治疗时代的感染风险:将机制与感染联系起来。
Blood Rev. 2018 Sep;32(5):387-399. doi: 10.1016/j.blre.2018.03.004. Epub 2018 Mar 16.
5
Risk of hepatitis B virus reactivation in patients treated with ibrutinib.接受依鲁替尼治疗的患者中乙型肝炎病毒再激活的风险。
Blood. 2018 Apr 26;131(17):1987-1989. doi: 10.1182/blood-2018-01-826495. Epub 2018 Feb 28.
6
Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.布鲁顿酪氨酸激酶抑制剂伊布替尼治疗血液系统恶性肿瘤相关感染事件的系统评价。
Eur J Haematol. 2018 Apr;100(4):325-334. doi: 10.1111/ejh.13020. Epub 2018 Feb 6.
7
Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.伊布替尼在法国复发/难治性慢性淋巴细胞白血病中的真实世界结果:428例患者的大型系列早期结果
Am J Hematol. 2017 Aug;92(8):E166-E168. doi: 10.1002/ajh.24773. Epub 2017 May 30.
8
Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies.利巴韦林用于预防血液系统恶性肿瘤患者的慢性肝炎
Emerg Infect Dis. 2015 Aug;21(8):1466-9. doi: 10.3201/eid2108.150199.
9
Hepatitis E: An emerging infection in high income countries.戊型肝炎:高收入国家的一种新出现的感染。
J Clin Virol. 2014 Feb;59(2):81-8. doi: 10.1016/j.jcv.2013.11.013. Epub 2013 Dec 11.
10
Genotype 3 diversity and quantification of hepatitis E virus RNA.基因型 3 的多样性和戊型肝炎病毒 RNA 的定量。
J Clin Microbiol. 2012 Mar;50(3):897-902. doi: 10.1128/JCM.05942-11. Epub 2012 Jan 11.